Abstract: Purpose/Background: Prolactin-related adverse effects contribute to nonadherence and adverse health consequences, particularly in women with severe mental illness. Treating these adverse effects may improve treatment acceptability, adherence, and long-term outcomes.
T
here are many sex differences in people with schizophrenia. For example, illness presentation is often 3 to 5 years later, women have fewer negative symptoms and more affective symptoms, and women have slower metabolism of some antipsychotic treatments as compared with men. 1, 2 Adverse effects are also known to be different in women and men with schizophrenia treated with antipsychotics. 1 Women may be more distressed by weight gain, have higher rates of cardiovascular disease, 1, 3 and have significantly higher rates of hyperprolactinemia. 1, 4, 5 Hyperprolactinemia is associated with many symptoms and adverse effects, some of which can be serious. Various consequences include menstrual abnormalities, galactorrhea, and sexual dysfunction. More long-term risks include breast cancer, pituitary tumors, and decreased bone mineral density. 6 A case-control study from the United Kingdom found that the use of a prolactin-elevating antipsychotics resulted in an increased odds of sustaining a hip fracture. 7 In people experiencing prolactin-related adverse effects, nonadherence to antipsychotic treatment is common. And, in a nationwide survey of almost 900 people with schizophrenia taking antipsychotic medications, almost 60% reported nonadherence, with prolactin-and endocrine-related effects being one of the commonly cited reasons, decreasing the odds of adherence by approximately 30%. 8 In addition, many of these symptoms are embarrassing or difficult for people to discuss with health care providers and may go unaddressed for years. 9 Furthermore, symptomatic hyperprolactinemia has been found to significantly increase the risk of suicide in people with schizophrenia. Hyperprolactinemia is relatively common during antipsychotic treatment in women. One study found that, among 194 people with schizophrenia or bipolar disorder receiving antipsychotics from a single community mental health facility in the United Kingdom, 38% had prolactin levels above the upper limit of normal, two thirds of whom had significantly elevated levels with potential clinical consequences. Women were particularly at risk of elevations and associated consequences, as more than 50% of women in the study had abnormal prolactin levels. 9 Women in general have higher levels than men, and women are often more prone to elevations with dopamine antagonist treatment. 11 Nonetheless, many studies do not separate prolactin levels in men and women when reporting results. A review by Bostwick et al 6 summarized that mean prolactin levels in women during 3 to 6 weeks of treatment with risperidone, paliperidone, and first-generation antipsychotics were greater than 100 ng/mL, with reference ranges generally considered less than 24 ng/mL.
Antipsychotics with tight binding to D 2 receptors are associated with the highest rates of hyperprolactinemia, 12 although there are interpersonal variations as well. The degree of prolactin elevation may be a dose-related effect, at least for some antipsychotics. 13 Risperidone and paliperidone are the biggest culprits among prolactin-elevating antipsychotics because of their low blood-brain barrier penetration, resulting in higher concentration in, and subsequent effect at, the pituitary gland.
14 Other antipsychotics may result in slight or transient elevations in prolactin, but including the higher-potency first-generation antipsychotics, such as haloperidol, but not to the extent to which is observed with risperidone and paliperidone. Low-potency first-generation agents and some of the newer second-generation antipsychotics are prolactin sparing. Female patients and clinicians alike are eager for options to better manage these distressing and less acceptable adverse effects seen with some antipsychotics.
In contrast to the D 2 antagonism of most other antipsychotics, aripiprazole is an antipsychotic with partial dopamine agonist activity at D 2 receptors. Aripiprazole has been shown to act as an agonist in pituitary cells at the molecular level, and thus, lactotroph cells may not become blocked by aripiprazole treatment. 15 In addition, aripiprazole treatment has been associated with significant decreases in serum prolactin levels. In a doubleblind, 6-week, randomized trial of aripiprazole or perphenazine to treat symptoms for treatment-resistant schizophrenia by Kane and colleagues, 16 mean prolactin levels decreased in the aripiprazole group from 33.4 ng/mL to 5.2 ng/mL, whereas prolactin levels in the perphenazine group remained unchanged at 35.8 ng/mL to 35.5 ng/mL. Another recent 4-week double-blind randomized trial comparing the efficacy and safety of risperidone or aripiprazole in persons with schizophrenia or schizoaffective disorder reported that prolactin levels were significantly decreased in the aripiprazole group (−9.0 ng/mL) compared with a mean increase of 55.4 ng/mL in the risperidone group. In this study, the percentage of participants with schizophrenia who had an abnormal prolactin levels (>25 ng/mL) at end point was significantly higher in the risperidone group (93%) than in the aripiprazole group (5%). 17 Our group has generated pilot data suggesting that up to 30 mg of aripiprazole resolves elevated prolactin in women with amenorrhea on haloperidol. 5 Twenty-one (88%) of 24 women in another previous open-label study of adjunct aripiprazole given to women with risperidone-induced amenorrhea experienced recurrence of menstrual cycles between 8 and 16 weeks, as well as significantly decreased prolactin levels from a mean of 96.6 ng/mL at baseline to 28.1 ng/mL. 18 The objective of this randomized, double-blind, placebocontrolled trial was to test the efficacy and tolerability of adjunct aripiprazole compared with placebo in premenopausal women with symptomatic hyperprolactinemia treated with antipsychotics on important and understudied outcomes such as galactorrhea, sexual dysfunction, and amenorrhea. This study is referred to the DAAMSEL study, Dopamine Partial Agonist Aripiprazole for the Management of Symptomatic ELevated Prolactin. 
MATERIALS AND METHODS

Participants
Inclusion Criteria
Premenopausal women (aged 18-50 years) who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia, schizoaffective disorder, or bipolar disorder were eligible. Women were required to be taking a stable dose of an antipsychotic for at least 2 months and considered to have stable symptoms by the treating psychiatrist. Only those taking prolactin-elevating antipsychotics, including risperidone, paliperidone, or high-potency first-generation antipsychotics (ie, haloperidol, perphenazine, loxapine, or fluphenazine), were recruited. Those enrolled also were required to have a prolactin greater than 24 ng/mL and evidence of a prolactin-related hormonal adverse effect (amenorrhea, oligomenorrhea, or galactorrhea) or significant sexual dysfunction (Arizona Sexual Experience Survey, Arizona Sexual Experience Scale [ASEX] >16). The presence of these adverse effects was determined by participant report/history and medical record/clinician interview. Oligomenorrhea was defined as infrequent, irregularly timed episodic bleeding occurring at intervals of more than 35 days from the previous menstrual cycle, and amenorrhea was defined as absence of menstruation for 3 menstrual cycles or 6 months. 19 Galactorrhea was defined as lactation or copious milk secretion as evaluated by trained clinicians upon breast examination. In addition, all women were required to score at least a 10/12 on the Evaluation to Sign Consent, which is used to document capacity to provide informed consent.
Exclusion Criteria
Women were excluded if they were considered postmenopausal. Any potential participant older than 45 years was assessed for menopausal symptoms including, but not limited to, hot flashes, depression, excitability, and fatigue using the modified Menstrual Symptom Rating Scale (MRS). A medical doctor evaluated and assessed all participants and did not permit enrollment of those with apparent perimenopausal or postmenopausal symptoms. Other exclusion criteria included a history of a pituitary tumor (microadenoma, macroadenoma, neoplasm) or Cushing disease, pregnancy or current postpregnancy lactation, DSM-IV-TR criteria for alcohol or substance abuse within the last month (excluding caffeine or nicotine), or medications that may affect prolactin or cause sexual dysfunction through dopaminergic effects (eg, metoclopramide, methyldopa, reserpine, amoxapine, droperidol, prochlorperazine, promethazine, bromocriptine, and cabergoline).
Medications that may affect sexual function unrelated to dopamine transmission were permitted only if receiving for more than 4 weeks (including, but not limited to, selective serotonin reuptake inhibitors, mood stabilizers, diuretics, antihypertensives, H 2 antagonists, bupropion). Magnetic resonance imaging was not completed for the evaluation of pituitary tumors; however, consultation to endrocrinology was available for potential patients if they had very high prolactin levels (>300 ng/mL) or were suspect for possible tumor.
Study Procedures
Participants were screened for eligibility and then randomized to 16 weeks of double-blind treatment with adjunct aripiprazole or placebo, while continuing their prior antipsychotic treatment.
Screening and Baseline
Screening involved 1 to 2 visits and a variety of assessments to determine eligibility. Participants were educated about the study and possible medication adverse effects and completed the Evaluation to Sign Consent prior to signing the informed consent. Psychiatric diagnosis was confirmed using the Structured Clinical Interview for DSM-IV. 20 All participants received a physical examination and reviewed their medical history with a medically accountable physician who assessed the participant for evidence of prolactin-related adverse effects, menopausal status, and study eligibility. Participants also completed a number of assessments including electrocardiograph, vital signs, pregnancy test, and blood work. Participants had a breast examination with a trained female clinician to determine if galactorrhea was present. Documented birth control was required during the study, with new prescription oral contraceptive not permitted and only long-term OC use permitted.
All participants were seen every 2 weeks for study evaluations, and phone contact occurred twice weekly to ensure completion of the menstrual diary. Salivary hormone assessments were completed weekly at home.
Study Assessments
Hormonal Adverse Effects DAAMSEL is noteworthy for the rigor in clinical assessment of hormonal effects directly in relation to menstrual cycle. To measure hormonal adverse effects, specifically menstrual periods and galactorrhea, participants completed menstrual diaries throughout the study. Each woman was taught to document daily in her menstrual diary whether she experienced bleeding or pain. The diary was formatted as a monthly calendar that prompted participants to indicate presence and degree of menstrual flow (spotting = 1, light = 2, moderate = 3, heavy = 4). If galactorrhea was detected at baseline, the participant was instructed to also note daily lactation in the menstrual diary. Participants were reminded to fill out this diary via phone twice weekly. This diary was then reviewed with research staff at biweekly study appointments to verify correct use of the diary and to track occurrence of menstrual bleeding. If the diary was found to be incomplete, staff would review a calendar with the participant and ask her to recall any menstrual bleeding (and lactation, if applicable) in the past 2 weeks. Staff then followed up with the participant over the phone more frequently to be sure the participant completed the diary prior to the next visit. Menstrual bleeding for 3 to 8 days followed by another 3 to 8 days of menstrual bleeding 21 to 35 days later constituted regaining a regular menstrual cycle.
Pilot data determined that a menstrual period should take 8 to 12 weeks to return after aripiprazole initiation. Thus, a 16-week trial was devised to allow time for 2 regular menstrual cycles. Participants experiencing galactorrhea also had breast examinations performed by clinical staff at their biweekly appointments. An absence of any lactation or milk discharge for at least 2 consecutive breast examinations was characterized as galactorrhea resolution. To control the effects of menstrual cycles on prolactin and hormone levels, menstruating participants were randomized to begin treatment on the seventh day after starting their menstrual period.
Sexual Function
Sexual function was assessed using ASEX. 21 The Female Sexual Distress Scale-Revised 22 and Female Sexual Function Index 23 were administered as secondary measures. The ASEX is a valid and reliable scale in people with schizophrenia or schizoaffective disorder consisting of 5 items rated 1 to 6, with higher scores indicating more sexual dysfunction. Total scores on the ASEX can range from 5 to 30, and a score of greater than 16 indicates sexual dysfunction. These scales were administered monthly.
Psychiatric Symptoms
Psychiatric symptoms were measured by the Brief Psychiatric Rating Scale (BPRS), 24 Scale for the Assessment of Negative Symptoms (SANS), 25 Calgary Depression Scale (CDS), 26 and Clinical Global Impression Scale (CGI). 27 The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 28 was used to assess neuropsychological status. We measured positive symptoms using the BPRS conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content symptom items. To assess negative symptoms, we subtracted the global items, inappropriate affect, poverty of speech, and attention items from the total score of the SANS. 29 These assessments were administered monthly.
Subject Wellness and Quality of Life
We measured wellness, quality of life, and satisfaction with treatment. The 36-item Short Form (SF-36) scale, 30 which incorporates physical and mental concepts, such as behavioral functioning, perceived well-being, social and role disability, and personal evaluations of overall health, was used to measure general health status. The Psychological General Well-being Schedule (PGWB), 31 a 22-item scale with a focus on inner personal experience consisting of 6 subscales of anxiety, depressed mood, positive well-being, self-control, general health, and vitality, was used to measure quality of life. The SF-36 and PGWB were performed at baseline and at weeks 4, 8, 12, and 16. At the conclusion of the study, participants were asked if they were (1) more likely to stay on their primary medication with the addition of aripiprazole, (2) happy that their menstrual period resumed (if irregularity present at baseline), and (3) happy that their sexual function improved (if dysfunction present at baseline). These were recorded on a 5-point Likert Scale.
Adverse Effect Measures
To assess adverse effects, we administered the Simpson-Angus Extrapyramidal Symptom Rating Scale (SAS), 32 Barnes Akathisia Rating Scale (BARS), 33 Abnormal Involuntary Movement Scale (AIMS), 34 and the Side Effect Checklist (SEC) at biweekly appointments.
Laboratory Assessments
Fasting serum prolactin was drawn every 2 weeks during the study. Normalization of prolactin was defined as a prolactin level of less than 24 ng/mL. Salivary estradiol and progesterone were collected at screening and then weekly after enrollment (kits were sent home). Salivary cortisol was collected at baseline, midpoint (week 8), and end point (week 16). Plasma osteocalcin and bonespecific alkaline phosphatase (measures of osteoblastic activity), as well as urinary N-telopeptide of type I collagen crosslinks and C-telopeptide of collagen crosslinks (measures of osteoclastic activity), were measured at baseline and then at weeks 4, 8, and 16. We measured the complete blood count, fasting glucose, lipids, thyroidstimulating hormone, parathyroid hormone, homocysteine and 25-hydroxy-vitamin D level at baseline, midpoint, and end point. All fasting laboratory measurements were drawn the morning of testing prior to breakfast. All laboratory measures were performed by a CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory, LabCorp, with the exception of salivary estradiol, progesterone, and cortisol, which were sent to ZRP Laboratory. Details on all laboratory assessments are found in Supplementary 
Study Medication and Randomization Procedures
Participants were randomized using a permuted block randomization sequence based on inpatient/outpatient status. Aripiprazole or matched placebo tablets were given in a double-blind fashion, which started at 5 mg orally daily and increased to 10 mg/d at the end of week 2. The dosage was increased at the end of week 8 to 15 mg/d in any participant who had not had any response in prolactin-related symptoms. The study medication was added to the ongoing antipsychotic regimens. Study physicians were instructed to avoid changing doses of other somatic and psychotropic medications throughout the study. Anticholinergic medications for extrapyramidal adverse effects (eg, benztropine and diphenhydramine), propranolol for akathisia, and benzodiazepines for anxiety or agitation (eg, lorazepam) could be prescribed as needed.
Statistical Analysis
All analyses were conducted on an intention-to-treat basis according to randomly assigned treatment. The primary outcome of the study, resolution of amenorrhea, oligomenorrhea, or galactorrhea, was analyzed at 2-sided α = 0.05. We compared percentages in whom hormonal adverse effects (galactorrhea and oligomenorrhea/ amenorrhea) had remitted by end of study (week 16) in the aripiprazole versus placebo groups using a Mantel-Haenszel χ 2 test at 2-sided α = 0.05. Sexual functioning, general well-being, This table presents demographic and clinical information for the DAAMSEL cohorts. Demographic information included for those randomized and exposed to drug for more than 2 weeks (n = 42); prolactin-related outcomes reported only for those with more than 8 weeks' drug exposure (n = 37). For baseline variables, there were no significant differences noted in demographic measures, clinical history, or medications (P > 0.05).
*Prolactin-related effects. AA indicates African American; W, white.
psychiatric symptoms, and laboratory measures were assessed using mixed-models analysis of covariance for repeated measurement of the form follow-up measurement = baseline measurement + treatment + week + treatment Â week, where within-subject correlation of repeated measurements is assessed with an unstructured covariance model and "week" is not treated as a continuous measure, but as a set of categorical indicators of the week at which a measurement is collected. With this model, the "treatment" term estimates the average (across follow-up weeks) difference between treatments, and the treatment Â week term assesses whether this difference varies over time. We performed a Kaplan-Meier survival curve analysis to examine time to normalization of prolactin, time to resolution of galactorrhea, and time to remission of sexual dysfunction using a log-rank χ
2
. The sample size of 46, although slightly smaller than the preplanned 25 per group, provided power of greater than 0.80 to detect large differences in prolactin change and resolution of galactorrhea (eg, 60% remission on aripiprazole vs 10% on placebo). It is important to note that the primary outcome could not be observed conclusively in those who withdrew before week 16. To assess sensitivity to dropout, we looked at how results would be altered if participants who withdrew before response was observed were imputed to be nonresponders.
RESULTS
Participants
Sixty participants with a DSM-IV-TR diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder were enrolled into the study. Fourteen were excluded prior to randomization for not meeting inclusion and exclusion criteria, and so, a total of 46 were randomized. See Supplementary Figure 1 The mean age was 36.6 ± 9.4 years, and 62% were African American. Approximately 70% reported having 2 prolactinrelated adverse effects present at baseline, and 30% had all 3. Detailed demographic information for all randomized participants exposed to study drug for longer than 2 weeks is provided in Table 1 . No statistically significant differences were noted in baseline characteristics. The mean aripiprazole dose used in the study was 11.7 ± 2.4 mg/d and was 14.4 ± 1.7 mg/d for placebo (F 112 = 9.66, P < 0.001). The mean baseline prolactin concentration was 84.3 ± 56.6 ng/mL (88.5 ± 68.1 ng/mL in the aripiprazole group and 79.5 ± 40.6 ng/mL in the placebo group). Among those completing at least 8 weeks of follow-up, at baseline, 23 (62%) of 37 had galactorrhea, 24 (65%) of 37 had oligomenorrhea/ amenorrhea and 25 (68%) of 37 had sexual dysfunction (Table 1) .
Prolactin
As shown in Figure 1 , the prolactin level significantly decreased in the aripiprazole group compared with placebo over 16 weeks (estimated difference, −26.3 ± 12.6; df = 35, P = 0.04), with the greatest drop occurring in the first week. It is important to note that even with this significant difference, normalization was not achieved in all women on aripiprazole. Kaplan-Meier survival curve analysis estimated that at week 1, 20% of aripiprazole participants had normalization of prolactin compared with 6% of placebo participants, and this increased to 35% at weeks 4 and 12 compared with 6% of placebo. At week 16, 45% of aripiprazole participants versus 12% of placebo participants had complete normalization of prolactin levels (log-rank χ 
Prolactin-Related Adverse Effects
Seventy-seven percent (10/13) of participants with galactorrhea in the aripiprazole group had improved or remitted symptoms versus 33% (4/12) in the placebo group (χ 2 1 = 4.8, P = 0.028). In the Kaplan-Meier survival curve analysis, the estimated rate of normalization of galactorrhea in the aripiprazole and placebo groups, respectively, was 29% versus 17% at week 4, 57% versus 33% at week 8, 71% versus 33% at week 12, and 79% versus 33% at week 16 (log-rank χ 2 1 = 3.8, P = 0.05). The difference in resumption of normal regular menstruation in the aripiprazole (6/13 [46%]) versus placebo groups (3/11 [27%]) was not statistically significant (P = 0.34). At any point during the study, menstrual bleeding occurred in 85% (11/13) with aripiprazole and 64% (7/11) in the placebo group (P = 0.24).
Normalization of sexual dysfunction (<16 on ASEX) occurred in 50% (7/14) with aripiprazole versus 9% (1/11) with placebo (χ 2 1 = 4.7, P = 0.03). Also, there were a significantly greater percentage of women who experienced a 20% reduction on the ASEX (25% [5/20] vs 0%) on aripiprazole compared with placebo (χ 2 1 = 4.9. P = 0.027). There were no significant group differences in the Female Sexual Distress Scale-Revised; the baseline and end point scores were 13.3 ± 11.8 and 9.0 ± 8.7, respectively, for aripiprazole and 7.6 ± 10.2 and 6.5 ± 11.3 for placebo (F 1,36 = 0.0, P = 0.97). There were also no significant group differences in the Female Sexual Function Index (P > 0.05). Although not significant, the relationship between change in prolactin and change in the ASEX in the aripiprazole group was r = 0.31, P = 0.18. There was no correlation noted between change in prolactin and change in the ASEX in the placebo group (r = 0.016, P = 0.95).
Clinical Symptoms
There were no significant treatment group differences in BPRS, SANS, or CGI scores (P > 0.05; Table 2 ). Robust response on the BPRS total score (>30% response) was noted in 3 (13%) of 24 in the aripiprazole group versus 0 of 20 in the placebo group (χ 2 1 = 2.42, P = 0.12). There was a significant treatment effect for the CDS total score (F 1,38.4 = 4.4, P = 0.04), which favored aripiprazole. There were no significant differences in RBANS composite score or the SF-36 or PGWB total scores. On the PGWB subscales of depressive symptoms and positive wellbeing, there was no change noted in the aripiprazole group and a significant improvement noted in the placebo group. One participant in the aripiprazole group, as noted earlier, discontinued because of worsening of positive symptoms.
Laboratory Results and Adverse Effects
The only noted difference in laboratory measures was a decrease in alkaline phosphatase with aripiprazole compared with placebo (Table 3) ; however, this was not observed in the bonespecific alkaline phosphatase. There were no significant group differences in any measures of bone health. There were no significant group differences seen in adverse effects, indicating that aripiprazole was well tolerated (Table 4) . Because akathisia is an adverse effect of aripiprazole, the BARS was used to assess this adverse effect. The baseline and end point scores on the BARS were 0.8 ± 2.2 and 0.5 ± 1.5 for aripiprazole and 0.6 ± 1.3 and 0.3 ± 1.2 for placebo (F 1,41 = 0.35, P = 0.56). There were also no significant group differences in change in SAS or AIMS total scores; baseline and end point SAS scores were 1.3 ± 1.9 and 0.8 ± 1.0 for aripiprazole and 0.9 ± 1.3 and 0.5 ± 0.7 for placebo (F 1,41 = 0.19, P = 0.67), and baseline and end point AIMS scores were 0.7 ± 1.5 and 0.5 ± 1.8 for aripiprazole and 0.5 ± 1.2 and 0.3 ± 0.8 for placebo (F 1,38 = 0.65, P = 0.43). Two participants were withdrawn because of adverse effects: one in the aripiprazole group due to nausea and one in the placebo group due to abdominal pain.
Participant Perceptions
Although a small sample, 80% of women on aripiprazole answered yes to feeling more inclined to take their risperidone with this add-on treatment (4/5 aripiprazole and 0/3 placebo; χ 2 1 = 4.8, P = 0.029). Overall, women were asked about satisfaction with the resolution of their menstrual periods and improvement with sexual dysfunction on a Likert scale of 1 to 5. Women rated a mean score of 3.6 ± 1.5 when asked how happy they were that menstrual periods resumed and a mean score of 4.6 ± 0.6 when asked about improvements in sexual function. This did not differ by group.
DISCUSSION
The 16-week DAAMSEL study, using multiple clinical and hormonal measures, reveals that the addition of relatively lowdose aripiprazole can achieve meaningful reductions in serum This table reports the baseline and end point scores for the psychiatric symptoms reported in the study. There was a statistical improvement in the PGWB global scale seen in the placebo group with no difference noted in the aripiprazole group. This improvement was seen in depressed mood and positive well-being.
prolactin levels, as well as facilitate demonstrable improvements in sexual function and galactorrhea among females who experience distressing antipsychotic-induced hyperprolactinemia. Adjunctive aripiprazole has been shown in a handful of randomized double-blind trials and a meta-analysis 35 to decrease prolactin; however, this is one of few published studies examining add-on aripiprazole for the treatment of symptomatic hyperprolactinemia in only female participants. Supplementary Table 2 , Supplemental Digital Content 3, http://links.lww.com/JCP/A507, lists all randomized, controlled, double-blind trials found in English databases. Most other published studies with prolactin as primary end point were shorter in duration (ie, 8 weeks) than our study of 16 weeks. The beneficial results of short-term trials may be due, in part, to the discontinuation of prolactin-elevating antipsychotics. In addition, the DAAMSEL study controlled for phase of the menstrual cycle, weekly pill counts, and completed biweekly breast examinations. Few other studies also collected hormonal information.
With regard to galactorrhea, we see a significant reduction in this adverse effect with approximately 80% of aripiprazole-treated participants having normalization at study end point. It is notable that while prolactin decreases in the first weeks, galactorrhea does take longer to resolve, with the majority of resolution of galactorrhea occurring at 2 to 3 months. Very few other studies have addressed this adverse effect through the use of regular standardized breast examinations. One other randomized trial that we previously completed found an improvement in galactorrhea. 5 In addition, an open-label study by Ranjbar and colleagues 36 found that prolactin normalization with add-on aripiprazole took approximately 84 days, but that resolution of galactorrhea was seen in 29% of patients at week 2, 57% at week 4, and then almost 80% by week 8, also confirming that it takes some time to resolve galactorrhea even after immediate prolactin decreases. This finding is new and important as breast evaluation for galactorrhea rarely occurs in both clinical practice and research, and this draws attention to the critical need to examine this adverse effect.
Our study did not detect a significant improvement in participant menstrual status, similar to other randomized controlled trials and open-label studies. 4, 37, 38 This may be due to the lack of normalization of prolactin in all participants or that both those with amenorrhea and oligomenorrhea were included in the study. Menstrual periods were randomly occurring in the majority of participants, making it difficult to operationalize an improvement definition. Also, we did examine time to any bleeding and time to the reinstatement of 2 regular menstrual periods; however, it may take longer periods to see normalization to regularly occurring menses in people lacking regular menstrual periods for years or decades. Improvement in sexual function was a major finding of our study. Not only did we see significantly greater number of people on adjunct aripiprazole with a significant drop in ASEX scores, but we also saw a greater number of those on adjunct aripiprazole with normalization of sexual functioning (50%). Only a few other randomized studies addressed sexual dysfunction using a standardized rating scale 4, 39 ; however, there is scant information on the effects of prolactin reduction on sexual function in women specifically. A few open-label studies have found that aripiprazole monotherapy or as an adjunct reduces sexual dysfunction in people with schizophrenia. [40] [41] [42] Sexual dysfunction is a significant underaddressed problem both in schizophrenia and in women. In fact, sexual dysfunction has been rated as one of the most distressing and frequently reported adverse effects with antipsychotic treatment 43 and associated with a poor quality of life. 44 In a few studies in schizophrenia, add-on aripiprazole was found to improve psychiatric symptoms, particularly negative symptoms, which we did not see in the current study. However, these studies were designed with psychiatric symptoms as the primary end point, enrolled participants with baseline symptom thresholds, and used doses as high as 30 mg, which is higher than those used in our study. 4, 5, [45] [46] [47] [48] In the most recent meta-analysis evaluating add-on aripiprazole, statistically significant reductions in Positive and Negative Symptom Scale and BPRS total scores were reported, with reduction in negative symptom scores driving most of these findings. The results of the studies in the metaanalysis were highly heterogeneous (I 2 = 78%-91%), and the GRADE analyses revealed overall low quality of evidence for these outcomes. In addition, most of the included studies were in Chinese participants, potentially affecting generalizability. 49 An earlier meta-analysis found no statistically significant improvement in any clinical scales and still reported low-quality evidence. 48 Potential improvement of clinical symptoms, especially negative symptoms, with aripiprazole requires further investigation. We saw mixed results on depressive symptoms: aripiprazole favoring treatment was associated with greater reductions on the CDS total score, whereas placebo was associated with greater reductions in PGWB depressive symptoms. The PGWB depression subfactor is composed of only 3 items (depressed, blue, and sad), whereas the CDS consists of 9 items that include other depressive aspects such as guilt, hopelessness, and self-depreciation. Aripiprazole may have more effect on other domains of depressive symptoms such as those observed in this study.
Given the high incidence of nonadherence in serious mental illnesses such as schizophrenia, the increase in desire to continue antipsychotic therapy is a major step toward maintaining psychiatric stabilization. 50 The benefit of reversing hyperprolactinemia with aripiprazole has had much recognition; however, the benefits to the women being treated with this strategy remain unclear. This study helps establish aripiprazole as a treatment in women with symptomatic hyperprolactinemia. We better understand rates of adverse effect occurrence, estimated treatment response, and time course to reduction in prolactin in this study by having used detailed assessments on menstrual cycle, breast examinations, and sexual function assessments. In summary, benefits of the strategy include improvement in prolactin, adverse effects, and satisfaction with treatment. This in turn could improve adherence and other longerterm consequences not studied. With using the strategy as monotherapy instead of adjunct treatment, it may decrease the risk of other long-term adverse effects, increased costs, and the burden of additional pills but has less evidence base, and switching from one antipsychotic to another has been associated with psychiatric exacerbation. Thus, there is a stronger evidence base for the efficacy and safety of adjunct aripiprazole therapy than switching to aripiprazole monotherapy. It is noteworthy that 16 weeks of adjunct aripiprazole treatment did not worsen metabolic adverse effects or movement disorder symptoms.
Our study is not without limitations. We were not able to objectively verify menstrual status and had to rely on self-report. Also, the study may not have been long enough to detect attenuation of bone changes or menstrual changes. It is also noteworthy that the study participants were overweight and obese as often seen with this population. Sexual dysfunction, galactorrhea, and amenorrhea at baseline may have partly contributed to other factors such as obesity, hormone imbalance, or other unknown factors. We were not able to assess causality of prolactin-related adverse effects, which may be why direct correlations between prolactin and sexual function were not significantly correlated. In addition, we did not assess bone density using dual-energy x-ray absorptiometry to measure bone loss. Lastly, polypharmacy is not without risk of other adverse effects. We did not observe adverse effects in this study; however, long-term adverse effects may occur.
CONCLUSIONS
Our study demonstrates that aripiprazole can be used in premenopausal women to reduce not only serum prolactin levels, but also prolactin-related adverse effects. Through this, patients are more likely to remain adherent to medications and therefore remain more stable psychiatrically. It is important to personalize treatment, and this strategy may help reduce untoward adverse effects in women stabilized on treatment and experiencing prolactin-related adverse effects. Longer-term studies are needed to examine the risks and benefits of long-time use.
